Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S. Consumer Advocate Urges U.S. Inspection Of Shanghai Hualian Plants

This article was originally published in PharmAsia News

Executive Summary

A U.S. consumer advocate says the U.S. FDA should inspect immediately all the plants of China's Shanghai Hualian drug maker in the wake of last year's scandal at one of its plants. Two officials of Shanghai Hualian, a division of Shanghai Pharmaceutical Group, were detained by Shanghai police during an investigation after nearly 200 cancer patients were harmed by Hualian leukemia drugs made at one of the division's plants that also produces mifepristone. The drug ingredient is the primary ingredient in the abortion drug RU-486. The division is the sole supplier of the controversial abortion drug, but a Shanghai regulator said the leukemia and RU-486 drugs were made at two different plants. Danco Laboratories has U.S. clearance for the drug as Mifeprex. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts